Fromm MF - Search Results

1

P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.

Fromm MF. Fromm MF. Int J Clin Pharmacol Ther. 2000 Feb;38(2):69-74. doi: 10.5414/cpp38069. Int J Clin Pharmacol Ther. 2000. PMID: 10706193 Review.

2

Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.

Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, Eichelbaum M. Dilger K, et al. Among authors: fromm mf. Pharmacogenetics. 1999 Oct;9(5):551-9. Pharmacogenetics. 1999. PMID: 10591535

3

Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue.

Kivistö KT, Bookjans G, Fromm MF, Griese EU, Münzel P, Kroemer HK. Kivistö KT, et al. Among authors: fromm mf. Br J Clin Pharmacol. 1996 Sep;42(3):387-9. doi: 10.1046/j.1365-2125.1996.42615.x. Br J Clin Pharmacol. 1996. PMID: 8877031 Free PMC article.

4

Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction.

Fromm MF, Dilger K, Busse D, Kroemer HK, Eichelbaum M, Klotz U. Fromm MF, et al. Br J Clin Pharmacol. 1998 Mar;45(3):247-55. doi: 10.1046/j.1365-2125.1998.00669.x. Br J Clin Pharmacol. 1998. PMID: 9517368 Free PMC article. Clinical Trial.

5

Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.

Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Pauli-Magnus C, et al. Among authors: fromm mf. Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):551-7. doi: 10.1007/s00210-001-0489-7. Naunyn Schmiedebergs Arch Pharmacol. 2001. PMID: 11770010

6

Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique.

von Richter O, Greiner B, Fromm MF, Fraser R, Omari T, Barclay ML, Dent J, Somogyi AA, Eichelbaum M. von Richter O, et al. Among authors: fromm mf. Clin Pharmacol Ther. 2001 Sep;70(3):217-27. doi: 10.1067/mcp.2001.117937. Clin Pharmacol Ther. 2001. PMID: 11557909 Clinical Trial.

7

Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing.

Busse D, Fromm MF, Mörike K, Drescher S, Kühlkamp V, Eichelbaum M. Busse D, et al. Among authors: fromm mf. Clin Pharmacol Ther. 2001 May;69(5):324-32. doi: 10.1067/mcp.2001.115125. Clin Pharmacol Ther. 2001. PMID: 11372000 Clinical Trial.

8

Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.

Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF. Pauli-Magnus C, et al. Among authors: fromm mf. J Pharmacol Exp Ther. 2000 May;293(2):376-82. J Pharmacol Exp Ther. 2000. PMID: 10773005

9

Loss of analgesic effect of morphine due to coadministration of rifampin.

Fromm MF, Eckhardt K, Li S, Schänzle G, Hofmann U, Mikus G, Eichelbaum M. Fromm MF, et al. Pain. 1997 Aug;72(1-2):261-7. doi: 10.1016/s0304-3959(97)00044-4. Pain. 1997. PMID: 9272811 Clinical Trial.

10

Stereoselectivity in drug metabolism and action: effects of enzyme inhibition and induction.

Kroemer HK, Fromm MF, Eichelbaum M. Kroemer HK, et al. Among authors: fromm mf. Ther Drug Monit. 1996 Aug;18(4):388-92. doi: 10.1097/00007691-199608000-00013. Ther Drug Monit. 1996. PMID: 8857556

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results